Identification of mutations at DNA topoisomerase I responsible for camptothecin resistance

Leng-Fang Wang, Chun Yuan Ting, Cheng Kai Lo, Jin Shan Su, Lyn A. Mickley, Antonio T. Fojo, Jacqueline Whang-Peng, Jaulang Hwang

Research output: Contribution to journalArticle

47 Citations (Scopus)

Abstract

A camptothecin-resistant cell line that exhibits more than 600-fold resistance to camptothecin, designated CPT(R)-2000, was established from mutagen-treated A2780 ovarian cancer cells. CPT(R)-2000 cells also exhibit 3- fold resistance to a DNA minor groove-binding ligand Ho33342, a different class of mammalian DNA topoisomerase I inhibitors. However, CPT(R)-2000 cells exhibit no cross-resistance toward drugs such as Adriamycin, amsacrine, vinblastine, and 4'-dimethyl-epipodophyllotoxin. The mRNA, protein levels, and enzyme-specific activity of DNA topoisomerase I are relatively the same in parental and CPT(R)-2000 cells. However, unlike the DNA topoisomerase I activity of parental cells, which can be inhibited by camptothecin, that of CPT(R)-2000 cells cannot. In addition, parental cells after camptothecin treatment results in a decrease in the level of DNA topoisomerase I, whereas CPT(R)-2000 cells are insensitive to camptothecin treatment. These results suggested that the mechanism of camptothecin resistance is most likely due to a DNA topoisomerase I structural mutation. This notion is supported by DNA sequencing results confirming that DNA topoisomerase I of CPT(R)-2000 is mutated at amino acid residues Gly 717 to Val and Thr 729 to Ile. We also used the yeast system to examine the mutation(s) responsible for camptothecin resistance. Our results show that each single amino acid change results in partial resistance, and the double mutation gives a synergetic effect on camptothecin resistance. Because both mutation sites are near the catalytic active center, this observation raises the possibility that camptothecin may act at the vicinity of the catalytic active site of the enzyme-camptothecin- DNA complex.

Original languageEnglish
Pages (from-to)1516-1522
Number of pages7
JournalCancer Research
Volume57
Issue number8
Publication statusPublished - 1997

Fingerprint

Camptothecin
Type I DNA Topoisomerase
Mutation
Catalytic Domain
Amsacrine
Podophyllotoxin
Topoisomerase I Inhibitors
Amino Acids
Vinblastine
DNA
Mutagens
Enzymes
DNA Sequence Analysis
Drug Resistance
Ovarian Neoplasms
Doxorubicin
Yeasts
Ligands
Cell Line

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Wang, L-F., Ting, C. Y., Lo, C. K., Su, J. S., Mickley, L. A., Fojo, A. T., ... Hwang, J. (1997). Identification of mutations at DNA topoisomerase I responsible for camptothecin resistance. Cancer Research, 57(8), 1516-1522.

Identification of mutations at DNA topoisomerase I responsible for camptothecin resistance. / Wang, Leng-Fang; Ting, Chun Yuan; Lo, Cheng Kai; Su, Jin Shan; Mickley, Lyn A.; Fojo, Antonio T.; Whang-Peng, Jacqueline; Hwang, Jaulang.

In: Cancer Research, Vol. 57, No. 8, 1997, p. 1516-1522.

Research output: Contribution to journalArticle

Wang, L-F, Ting, CY, Lo, CK, Su, JS, Mickley, LA, Fojo, AT, Whang-Peng, J & Hwang, J 1997, 'Identification of mutations at DNA topoisomerase I responsible for camptothecin resistance', Cancer Research, vol. 57, no. 8, pp. 1516-1522.
Wang L-F, Ting CY, Lo CK, Su JS, Mickley LA, Fojo AT et al. Identification of mutations at DNA topoisomerase I responsible for camptothecin resistance. Cancer Research. 1997;57(8):1516-1522.
Wang, Leng-Fang ; Ting, Chun Yuan ; Lo, Cheng Kai ; Su, Jin Shan ; Mickley, Lyn A. ; Fojo, Antonio T. ; Whang-Peng, Jacqueline ; Hwang, Jaulang. / Identification of mutations at DNA topoisomerase I responsible for camptothecin resistance. In: Cancer Research. 1997 ; Vol. 57, No. 8. pp. 1516-1522.
@article{f6f046d9ac9247debf55827dce74755b,
title = "Identification of mutations at DNA topoisomerase I responsible for camptothecin resistance",
abstract = "A camptothecin-resistant cell line that exhibits more than 600-fold resistance to camptothecin, designated CPT(R)-2000, was established from mutagen-treated A2780 ovarian cancer cells. CPT(R)-2000 cells also exhibit 3- fold resistance to a DNA minor groove-binding ligand Ho33342, a different class of mammalian DNA topoisomerase I inhibitors. However, CPT(R)-2000 cells exhibit no cross-resistance toward drugs such as Adriamycin, amsacrine, vinblastine, and 4'-dimethyl-epipodophyllotoxin. The mRNA, protein levels, and enzyme-specific activity of DNA topoisomerase I are relatively the same in parental and CPT(R)-2000 cells. However, unlike the DNA topoisomerase I activity of parental cells, which can be inhibited by camptothecin, that of CPT(R)-2000 cells cannot. In addition, parental cells after camptothecin treatment results in a decrease in the level of DNA topoisomerase I, whereas CPT(R)-2000 cells are insensitive to camptothecin treatment. These results suggested that the mechanism of camptothecin resistance is most likely due to a DNA topoisomerase I structural mutation. This notion is supported by DNA sequencing results confirming that DNA topoisomerase I of CPT(R)-2000 is mutated at amino acid residues Gly 717 to Val and Thr 729 to Ile. We also used the yeast system to examine the mutation(s) responsible for camptothecin resistance. Our results show that each single amino acid change results in partial resistance, and the double mutation gives a synergetic effect on camptothecin resistance. Because both mutation sites are near the catalytic active center, this observation raises the possibility that camptothecin may act at the vicinity of the catalytic active site of the enzyme-camptothecin- DNA complex.",
author = "Leng-Fang Wang and Ting, {Chun Yuan} and Lo, {Cheng Kai} and Su, {Jin Shan} and Mickley, {Lyn A.} and Fojo, {Antonio T.} and Jacqueline Whang-Peng and Jaulang Hwang",
year = "1997",
language = "English",
volume = "57",
pages = "1516--1522",
journal = "Cancer Research",
issn = "0008-5472",
publisher = "American Association for Cancer Research Inc.",
number = "8",

}

TY - JOUR

T1 - Identification of mutations at DNA topoisomerase I responsible for camptothecin resistance

AU - Wang, Leng-Fang

AU - Ting, Chun Yuan

AU - Lo, Cheng Kai

AU - Su, Jin Shan

AU - Mickley, Lyn A.

AU - Fojo, Antonio T.

AU - Whang-Peng, Jacqueline

AU - Hwang, Jaulang

PY - 1997

Y1 - 1997

N2 - A camptothecin-resistant cell line that exhibits more than 600-fold resistance to camptothecin, designated CPT(R)-2000, was established from mutagen-treated A2780 ovarian cancer cells. CPT(R)-2000 cells also exhibit 3- fold resistance to a DNA minor groove-binding ligand Ho33342, a different class of mammalian DNA topoisomerase I inhibitors. However, CPT(R)-2000 cells exhibit no cross-resistance toward drugs such as Adriamycin, amsacrine, vinblastine, and 4'-dimethyl-epipodophyllotoxin. The mRNA, protein levels, and enzyme-specific activity of DNA topoisomerase I are relatively the same in parental and CPT(R)-2000 cells. However, unlike the DNA topoisomerase I activity of parental cells, which can be inhibited by camptothecin, that of CPT(R)-2000 cells cannot. In addition, parental cells after camptothecin treatment results in a decrease in the level of DNA topoisomerase I, whereas CPT(R)-2000 cells are insensitive to camptothecin treatment. These results suggested that the mechanism of camptothecin resistance is most likely due to a DNA topoisomerase I structural mutation. This notion is supported by DNA sequencing results confirming that DNA topoisomerase I of CPT(R)-2000 is mutated at amino acid residues Gly 717 to Val and Thr 729 to Ile. We also used the yeast system to examine the mutation(s) responsible for camptothecin resistance. Our results show that each single amino acid change results in partial resistance, and the double mutation gives a synergetic effect on camptothecin resistance. Because both mutation sites are near the catalytic active center, this observation raises the possibility that camptothecin may act at the vicinity of the catalytic active site of the enzyme-camptothecin- DNA complex.

AB - A camptothecin-resistant cell line that exhibits more than 600-fold resistance to camptothecin, designated CPT(R)-2000, was established from mutagen-treated A2780 ovarian cancer cells. CPT(R)-2000 cells also exhibit 3- fold resistance to a DNA minor groove-binding ligand Ho33342, a different class of mammalian DNA topoisomerase I inhibitors. However, CPT(R)-2000 cells exhibit no cross-resistance toward drugs such as Adriamycin, amsacrine, vinblastine, and 4'-dimethyl-epipodophyllotoxin. The mRNA, protein levels, and enzyme-specific activity of DNA topoisomerase I are relatively the same in parental and CPT(R)-2000 cells. However, unlike the DNA topoisomerase I activity of parental cells, which can be inhibited by camptothecin, that of CPT(R)-2000 cells cannot. In addition, parental cells after camptothecin treatment results in a decrease in the level of DNA topoisomerase I, whereas CPT(R)-2000 cells are insensitive to camptothecin treatment. These results suggested that the mechanism of camptothecin resistance is most likely due to a DNA topoisomerase I structural mutation. This notion is supported by DNA sequencing results confirming that DNA topoisomerase I of CPT(R)-2000 is mutated at amino acid residues Gly 717 to Val and Thr 729 to Ile. We also used the yeast system to examine the mutation(s) responsible for camptothecin resistance. Our results show that each single amino acid change results in partial resistance, and the double mutation gives a synergetic effect on camptothecin resistance. Because both mutation sites are near the catalytic active center, this observation raises the possibility that camptothecin may act at the vicinity of the catalytic active site of the enzyme-camptothecin- DNA complex.

UR - http://www.scopus.com/inward/record.url?scp=0030899190&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0030899190&partnerID=8YFLogxK

M3 - Article

C2 - 9108454

AN - SCOPUS:0030899190

VL - 57

SP - 1516

EP - 1522

JO - Cancer Research

JF - Cancer Research

SN - 0008-5472

IS - 8

ER -